A co-crystal is defined as a single crystalline structure composed of two or more components with no proton transfer which are solid at room temperature. Our group has come up with the following rationale selection of co-formers for initial co-crystal screening: 1) selection of co-formers with the highest potential for hydrogen bonding with the API and 2) selection of co-formers with diversity of secondary structural characteristics. We demonstrate the feasibility of this technique with a Novartis drug candidate A. In the first tier, 20 co-formers were screened and two hits were identified. By examining the two co-formers, which worked from the first round, a second round of screening was undertaken with more focused chemical matter. Nineteen co-crystal formers closely related to the two hits in the first screen were screened in the second tier. From this screen five hits were identified. All the hits were compared for their physical and chemical stability and dissolution profile. Based on the comparison 4-aminobenzoic co-crystal was chosen for in-vivo comparison with the free form. The co-crystal had 12 times higher exposure than the free form thus overcoming the solubility limited exposure.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejps.2016.02.017 | DOI Listing |
Int J Pharm
December 2024
Pharmaceutical and Molecular Biotechnology Research Centre, South East Technological University, Waterford, Ireland; SSPC, The Research Ireland Centre for Pharmaceuticals, South East Technological University, Waterford, Ireland. Electronic address:
J Pharm Sci
January 2025
Material Sciences Department, Pharmaron, 6 Taihe Road, Beijing 100176, China.
This survey provides a comprehensive analysis of solid form screens for 476 new chemical entities (NCEs) conducted at Pharmaron from 2016 to 2023. The findings from this survey reveal notable trends in polymorphism, salt formation, crystallization behavior and molecular weight (MW) distribution of the NCEs evaluated. Most solid form screens were conducted to select the preferred solid form for Investigational New Drug (IND) enabling projects, others were for candidate selection or late-stage development.
View Article and Find Full Text PDFHeliyon
April 2024
Department of Pharmaceutics, B. K. Mody Government Pharmacy College, Rajkot, India.
The objective of this review is, to discuss recent advancements in screening methods for co-formers, evaluation cum confirmation methods and co-crystallization with examples. Co-crystals are considered as a new form of an old drug entity. Co-crystals improve the stability, hygroscopicity, solubility, dissolution, and physicochemical properties of pure drugs without altering chemical and pharmacological properties.
View Article and Find Full Text PDFDalton Trans
April 2024
Faculty of Chemistry, Warsaw University of Technology, Noakowsiego 3, 00-664 Warsaw, Poland.
Polymorphism and co-crystallization have gradually gained attention as new tools in the development of modern crystalline functional materials. However, the study on the selective self-assembly of metal clusters into multicomponent crystals is still in its infancy. Herein, we present the synthesis and characterization of two new heteroleptic hydroxido-acetato and acetato Co(II) clusters [Co(OH)(OAc)()] (1) and [Co(OAc)()] (2) incorporating auxiliary 2-pyrrolidinoethoxylate () ligands.
View Article and Find Full Text PDFPharm Dev Technol
December 2023
Department of Pharmaceutics and Industrial Pharmacy, Modern University for Technology and Information (MTI), Mokattam, Egypt Cairo.
This study aims to improve the RXB bioavailability using hybrid nanoparticles. A modified melt dispersion technique created different formulas with varying GMO-SAIB: RXB and GMO: SAIB ratios, with fixed GMO-SAIB: poloxamer 407 ratios. The PS, PDI, ZP, and EE were measured to determine the optimal formula, which was selected using Design-Expert™ software.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!